Personal information

United States

Biography

Dr. Hymes is EVP, Global Head of Clinical Affairs for Fresenius Medical Care; CMO for Fresenius Kidney Care; and Chairman, Pharmacy & Therapeutics Committee. A graduate of Yale College and the Albert Einstein School of Medicine, board certified in internal medicine, nephrology and critical care.

Activities

Employment (4)

Fresenius Medical Care: Waltham, MA, US

2020-12 to present | EVP, Global Head of Clinical Affairs and CMO, Fresenius Kidney Care (Global Medical Office)
Employment
Source: Self-asserted source
Jeffrey Hymes

American College of Physicians: Philadelphia, PA, US

2003 to present | Member
Employment
Source: Self-asserted source
Jeffrey Hymes

Fresenius Kidney Care: Waltham, MA, US

2012-01 to 2020-12 | Sr. VP, CMO, Chair, Pharmacy & Therapeutics Commitee (Kidney Disease Initiatives)
Employment
Source: Self-asserted source
Jeffrey Hymes

Fresenius Medical Care North America: Waltham, MA, US

2007 to 2011 | Associate CMO, Chair, Pharmacy & Therapeutics Committee (Medical Office)
Employment
Source: Self-asserted source
Jeffrey Hymes

Education and qualifications (6)

Boston University Medical Center: Boston, MA, US

1981 to 1983 | Research Fellow in Nephrology (Medicine)
Education
Source: Self-asserted source
Jeffrey Hymes

Boston University Medical Center: Boston, MA, US

1980 to 1981 | Fellow in Clinical Nephrology (Medicine)
Education
Source: Self-asserted source
Jeffrey Hymes

Yale-New Haven Hospital: New Haven, CT, US

1978 to 1980 | Asst. Resident (Medicine)
Education
Source: Self-asserted source
Jeffrey Hymes

Yale-New Haven Hospital: New Haven, CT, US

1977 to 1978 | Intern (Medicine)
Education
Source: Self-asserted source
Jeffrey Hymes

Albert Einstein College of Medicine: Bronx, New York, US

1973 to 1977 | M.D. (Medical )
Education
Source: Self-asserted source
Jeffrey Hymes

Yale University: New Haven, CT, US

1970 to 1974 | B.A. (Molecular Biophysics and Biochemistry)
Education
Source: Self-asserted source
Jeffrey Hymes

Works (12)

Antihypertensive Drug Treatment and the Risk for Intrahemodialysis Hypotension

Clinical Journal of the American Society of Nephrology
2024-10 | Journal article
Contributors: Carmine Zoccali; Giovanni Tripepi; Paola Carioni; Edouard L. Fu; Friedo Dekker; Vianda Stel; Kitty J. Jager; Francesca Mallamaci; Jeffrey L. Hymes; Franklin W. Maddux et al.
Source: check_circle
Crossref

Management of Patients with Multidrug-Resistant Organisms in Outpatient Dialysis Facilities

Clinical Journal of the American Society of Nephrology
2024-05 | Journal article
Contributors: Mary Dittrich; Jeffrey Silberzweig; Jeffrey L. Hymes; Jeff Giullian; Gopa Green; Leslie P. Wong; Barry I. Freedman; J. Ganesh Bhat; Leslie Spry; Robert Taylor et al.
Source: check_circle
Crossref

Prediction of Gastrointestinal Bleeding Hospitalization in Hemodialysis

2023-02-02 | Preprint
Contributors: John W. Larkin; Suman Lama; Sheetal Chaudhuri; Joanna Willetts; Anke C. Winter; Yue Jiao; Manuela Stauss-Grabo; Len A. Usvyat; Jeffrey L. Hymes; Franklin W. Maddux et al.
Source: check_circle
Crossref

What We Learned from Ebola: Preparing Dialysis Units for the Next Outbreak.

Clinical journal of the American Society of Nephrology : CJASN
2018-04 | Journal article
Contributors: Boyce JM; Hymes JL
Source: Self-asserted source
Jeffrey Hymes via Europe PubMed Central

Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap.

American journal of kidney diseases : the official journal of the National Kidney Foundation
2017-02 | Journal article
Contributors: Hymes JL; Mooney A; Van Zandt C; Lynch L; Ziebol R; Killion D
Source: Self-asserted source
Jeffrey Hymes via Europe PubMed Central

Incident diabetic foot ulcers and mortality in hemodialysis patients.

Hemodialysis international. International Symposium on Home Hemodialysis
2017-01 | Journal article
Contributors: Garimella PS; Wang W; Lin SF; Hymes J; Lacson E
Source: Self-asserted source
Jeffrey Hymes via Europe PubMed Central

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

Journal of the American Society of Nephrology : JASN
2016-11 | Journal article
Contributors: Nigwekar SU; Zhao S; Wenger J; Hymes JL; Maddux FW; Thadhani RI; Chan KE
Source: Self-asserted source
Jeffrey Hymes via Europe PubMed Central

Introduction: Role of the medical director series.

Clinical journal of the American Society of Nephrology : CJASN
2015-02 | Journal article
Contributors: Provenzano R; Hymes JL
Source: Self-asserted source
Jeffrey Hymes via Europe PubMed Central

Associates of cardiopulmonary arrest in the perihemodialytic period.

International journal of nephrology
2014 | Journal article
Contributors: Flythe JE; Li NC; Lin SF; Brunelli SM; Hymes J; Lacson E
Source: Self-asserted source
Jeffrey Hymes via Europe PubMed Central

Anaphylaxis and hypotension after administration of peginesatide.

The New England journal of medicine
2014-05 | Journal article
Contributors: Bennett CL; Jacob S; Hymes J; Usvyat LA; Maddux FW
Source: Self-asserted source
Jeffrey Hymes via Europe PubMed Central

Sodium thiosulfate therapy for calcific uremic arteriolopathy.

Clinical journal of the American Society of Nephrology : CJASN
2013-07 | Journal article
Contributors: Nigwekar SU; Brunelli SM; Meade D; Wang W; Hymes J; Lacson E
Source: Self-asserted source
Jeffrey Hymes via Europe PubMed Central

Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

Journal of the American Society of Nephrology : JASN
2012-09 | Journal article
Contributors: Chan KE; Warren HS; Thadhani RI; Steele DJ; Hymes JL; Maddux FW; Hakim RM
Source: Self-asserted source
Jeffrey Hymes via Europe PubMed Central